Abstract
Saliva is a readily available specimen that can be collected by non-invasive procedures and contains many drugs of interest in screening and diagnosis. It is obtained by a painless and non invasive method of sampling; it contains the free fraction of drugs and therefore it is a good indicator of intoxication state. Inspite of its usefulness, only a few studies on long-term storage have been conducted for some drugs of abuse, while methadone stability have not been investigated yet. This lack in standardization and the scarcity of analytical protocols actually restrict saliva applications. Authors studied methadone stability on saliva during 12 months. Fifty-nine saliva samples were collected from heroin addicts in methadone treatment with the Cozart Rapiscan Collection procedure. The samples, spiked with tri-deuterated internal standards analogs of methadone and 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate (EDDP), were submitted to Solid Phase MicroExtraction-Gas Chromatography/Mass Spectrometry (SPME-GC/MS) technique. Quantitative determinations of methadone and EDDP were performed immediately and after various intervals (one month, two months, twelve months). The results obtained from this experiment show that methadone is sufficiently stable at 4° C until 2 months, while a decrease have been observed for EDDP. These preliminary data prove the need to perform the analysis in a brief time, to avoid loss of EDDP. For the correct use of this biological matrix, more research and guidelines are recommended for drug testing on saliva.
Keywords: Saliva, methadone, stability, SPME-GC/MS
Drug Metabolism Letters
Title: Stability of Methadone and Its Main Metabolite in Oral Fluid
Volume: 2 Issue: 2
Author(s): Nadia Fucci and Nadia De Giovanni
Affiliation:
Keywords: Saliva, methadone, stability, SPME-GC/MS
Abstract: Saliva is a readily available specimen that can be collected by non-invasive procedures and contains many drugs of interest in screening and diagnosis. It is obtained by a painless and non invasive method of sampling; it contains the free fraction of drugs and therefore it is a good indicator of intoxication state. Inspite of its usefulness, only a few studies on long-term storage have been conducted for some drugs of abuse, while methadone stability have not been investigated yet. This lack in standardization and the scarcity of analytical protocols actually restrict saliva applications. Authors studied methadone stability on saliva during 12 months. Fifty-nine saliva samples were collected from heroin addicts in methadone treatment with the Cozart Rapiscan Collection procedure. The samples, spiked with tri-deuterated internal standards analogs of methadone and 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate (EDDP), were submitted to Solid Phase MicroExtraction-Gas Chromatography/Mass Spectrometry (SPME-GC/MS) technique. Quantitative determinations of methadone and EDDP were performed immediately and after various intervals (one month, two months, twelve months). The results obtained from this experiment show that methadone is sufficiently stable at 4° C until 2 months, while a decrease have been observed for EDDP. These preliminary data prove the need to perform the analysis in a brief time, to avoid loss of EDDP. For the correct use of this biological matrix, more research and guidelines are recommended for drug testing on saliva.
Export Options
About this article
Cite this article as:
Fucci Nadia and Giovanni De Nadia, Stability of Methadone and Its Main Metabolite in Oral Fluid, Drug Metabolism Letters 2008; 2 (2) . https://dx.doi.org/10.2174/187231208784040979
DOI https://dx.doi.org/10.2174/187231208784040979 |
Print ISSN 1872-3128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-0758 |
Related Articles
-
Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry The Roles of Membrane for Electrical Communication in a Biosystem
Neuroscience and Biomedical Engineering (Discontinued) Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression
Current Signal Transduction Therapy PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Current Pharmaceutical Design Machine Learning Algorithms for Predicting Protein Folding Rates and Stability of Mutant Proteins: Comparison with Statistical Methods
Current Protein & Peptide Science Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition
Current Neuropharmacology Surgical Treatment of the Sleep Apnea Syndrome in the Twenty-First Century
Current Respiratory Medicine Reviews Evidence that Pregnancy Specific Glycoproteins Regulate T-Cell Function and Inflammatory Autoimmune Disease During Pregnancy
Current Drug Targets - Inflammation & Allergy Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Innovations in Endodontic Filling Materials: Guttapercha vs Resilon
Current Pharmaceutical Design Elderly Hypertensive Patients: Silent White Matter Lesions, Blood Pressure Variability, Baroreflex Impairment and Cognitive Deterioration
Current Hypertension Reviews Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Role of Dietary Gluten in Development of Celiac Disease and Type I Diabetes: Management Beyond Gluten-Free Diet
Current Medicinal Chemistry The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Commentary-1 (Research Highlights: USP30 Regulates the Mitophagy-Mediated Neuroprotection in Parkinson’s Disease)
CNS & Neurological Disorders - Drug Targets